Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

NCT03733535 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Asthma; Eosinophilic

Interventions

DRUG: Benralizumab
DRUG: 129 Xenon

Sponsor

Dr. Grace Parraga

Collaborators

[object Object]